Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NMRA
Upturn stock ratingUpturn stock rating

Neumora Therapeutics, Inc. (NMRA)

Upturn stock ratingUpturn stock rating
$0.73
Last Close (24-hour delay)
Profit since last BUY-28.43%
upturn advisory
WEAK BUY
BUY since 14 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: NMRA (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $7.05

1 Year Target Price $7.05

Analysts Price Target For last 52 week
$7.05Target price
Low$0.61
Current$0.73
high$17.19

Analysis of Past Performance

Type Stock
Historic Profit -41.69%
Avg. Invested days 22
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 122.43M USD
Price to earnings Ratio -
1Y Target Price 7.05
Price to earnings Ratio -
1Y Target Price 7.05
Volume (30-day avg) 8
Beta -
52 Weeks Range 0.61 - 17.19
Updated Date 06/30/2025
52 Weeks Range 0.61 - 17.19
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.61

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -48.51%
Return on Equity (TTM) -79.05%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -125987998
Price to Sales(TTM) -
Enterprise Value -125987998
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -4.65
Shares Outstanding 161748000
Shares Floating 85865502
Shares Outstanding 161748000
Shares Floating 85865502
Percent Insiders 27.57
Percent Institutions 60.21

Analyst Ratings

Rating 3
Target Price 7.05
Buy 2
Strong Buy 1
Buy 2
Strong Buy 1
Hold 5
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Neumora Therapeutics, Inc.

stock logo

Company Overview

overview logo History and Background

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2019, focused on developing novel therapies for brain diseases. The company aims to address unmet needs in neuropsychiatric disorders and neurodegenerative diseases.

business area logo Core Business Areas

  • Neuropsychiatric Disorders: Developing therapies for major depressive disorder (MDD), schizophrenia, and other psychiatric illnesses.
  • Neurodegenerative Diseases: Researching and developing treatments for neurodegenerative conditions like Alzheimer's disease and Parkinson's disease.

leadership logo Leadership and Structure

The leadership team consists of experienced executives in drug development and commercialization. The organizational structure is typical of a biopharmaceutical company, with dedicated research, development, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • Navacaprant: A Kappa Opioid Receptor (KOR) antagonist currently in Phase 3 development for Major Depressive Disorder (MDD). Market share data is not yet available as the product is not commercialized. Competitors include traditional antidepressants (SSRIs, SNRIs) and other novel therapies in development by companies like Axsome Therapeutics (AXSM).
  • NMRA-266: A selective vasopressin 1A receptor (V1AR) antagonist in Phase 2 development for Social Anxiety Disorder (SAD). Market share data is not yet available. Competitors include SSRIs, SNRIs, and other anxiolytics. Companies like BioXcel Therapeutics (BTAI) are also developing treatments for anxiety disorders.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry focused on neurological and psychiatric disorders is growing, driven by increasing prevalence and unmet medical needs. The industry is characterized by high research and development costs, regulatory hurdles, and competition.

Positioning

Neumora Therapeutics is positioned as an innovator in the neuropsychiatric and neurodegenerative disease space, focusing on novel targets and mechanisms of action. Its competitive advantage lies in its experienced team and promising pipeline.

Total Addressable Market (TAM)

The TAM for neuropsychiatric and neurodegenerative disease therapies is estimated to be hundreds of billions of dollars globally. Neumora is positioned to capture a portion of this market with successful development and commercialization of its pipeline assets.

Upturn SWOT Analysis

Strengths

  • Strong pipeline of novel drug candidates
  • Experienced management team
  • Focus on unmet medical needs
  • Strong financial backing

Weaknesses

  • Clinical trial risks
  • Regulatory hurdles
  • Limited commercialization experience
  • High cash burn rate

Opportunities

  • Expanding pipeline through internal research and development
  • Partnering with larger pharmaceutical companies
  • Acquiring complementary technologies or assets
  • Expanding into new therapeutic areas

Threats

  • Competition from established pharmaceutical companies
  • Failure of clinical trials
  • Changes in regulatory environment
  • Pricing pressures

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • AXSM
  • BIIB
  • VRTX

Competitive Landscape

Neumora competes with larger, more established pharmaceutical companies. Neumora's advantage lies in its novel targets and mechanisms of action, while its disadvantage is its limited resources and commercialization experience.

Growth Trajectory and Initiatives

Historical Growth: Growth is primarily driven by advancement of pipeline candidates through clinical trials.

Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst estimates will vary depending on the stage of clinical development.

Recent Initiatives: Recent initiatives include advancing Navacaprant into Phase 3 clinical trials, progressing NMRA-266, and securing additional funding.

Summary

Neumora Therapeutics is a promising biopharmaceutical company with a focus on developing novel therapies for brain diseases. Its success hinges on the positive outcomes of its clinical trials, particularly for its lead compound, Navacaprant. Although Neumora faces the typical challenges associated with clinical-stage companies, its strong pipeline and experienced management team provide a solid foundation for future growth. They need to successfully navigate regulatory hurdles and compete with established pharmaceutical players to realize its full potential. It is an early-stage company with plenty to prove.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports (where available)
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share estimates are approximate and based on available data.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Neumora Therapeutics, Inc.

Exchange NASDAQ
Headquaters Watertown, MA, United States
IPO Launch date 2023-09-14
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 103
Full time employees 103

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.